How the MYD88 L265P gene change affects B‑cell lymphomas
Investigating and modeling MYD88L265P and co-occurring mutations in mature B-cell malignancies
Researchers are using lab models to learn how a common MYD88 L265P gene change alters B cells and contributes to B‑cell lymphomas, aiming to help people with lymphoplasmacytic lymphoma and certain diffuse large B‑cell lymphomas.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11146368 on NIH RePORTER |
What this research studies
From a patient's view, the team is studying a specific genetic change called MYD88 L265P that is common in some B‑cell lymphomas. They compare the mutant protein to the normal version using engineered models of activated B cells and follow how the protein behaves, triggers NF‑κB signaling, and interacts with other mutations. Much of the work uses specially made mice and molecular lab tests to see whether and how the mutation drives cancer development. The research looks for patterns that could point to new targets for diagnosis or treatment.
Who could benefit from this research
Good fit: People with lymphoplasmacytic lymphoma (including Waldenström macroglobulinemia) or activated B‑cell–type diffuse large B‑cell lymphoma who have the MYD88 L265P mutation would be most directly relevant to this work.
Not a fit: Patients with unrelated cancers or B‑cell lymphomas that do not carry the MYD88 L265P mutation are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could point to new targets for drugs or tests that better diagnose and treat MYD88‑driven B‑cell lymphomas.
How similar studies have performed: Previous studies have linked MYD88 L265P to lymphoma cell survival and early targeted therapy efforts, but the exact role in starting lymphoma and interactions with other mutations remains less well understood, so this project builds on known findings while exploring new mechanisms.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Carrasco, Ruben D — Dana-Farber Cancer Inst
- Study coordinator: Carrasco, Ruben D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.